|
|
|
|
|
|
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
A Phase II, Randomized, Assessor-blind, Multicenter, Multi-dose, Placebo-controlled Study Assessing the Safety and Anti-coronavirus Response of Brequinar Combined With Dipyridamole in Patients With Mild to Moderate SARS-CoV-2 Infection.
A Phase 2 multi-center, assessor-blind, randomized study to assess the safety, tolerability, and antiviral activity of brequinar in combination with dipyridamole.
A phase II, randomized, assessor-blind, multicenter, multi-dose, placebo-controlled study assessing the safety and anti-coronavirus response of brequinar combined with dipyridamole in patients with mild to moderate SARS-CoV-2 infection.
100 项与 PDE3A x DHODH 相关的临床结果
100 项与 PDE3A x DHODH 相关的转化医学
0 项与 PDE3A x DHODH 相关的专利(医药)